DSpace Repository

A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART

Show simple item record

dc.contributor Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Gómez, Carmen E.
dc.contributor.author Perdiguero, Beatriz
dc.contributor.author García Arriaza, Juan
dc.contributor.author Cepeda, Victoria
dc.contributor.author Sánchez-Sorzano, Carlos Óscar
dc.contributor.author Mothe, B.
dc.contributor.author Jiménez, José Luis
dc.contributor.author Muñoz Fernández, María Ángeles
dc.contributor.author Gatell, J.M.
dc.contributor.author López Bernaldo de Quirós, Juan Carlos
dc.contributor.author Brander, Christian
dc.contributor.author Garcia, Felipe
dc.contributor.author Esteban, Mariano
dc.date.accessioned 2016-02-01T16:52:31Z
dc.date.available 2016-02-01T16:52:31Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Elena Gomez, C., Perdiguero, B., Garcia-Arriaza, J., Cepeda, V., Oscar Sanchez-Sorzano, C., Mothe, B., et al. (2015). A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS One, 10(11), e0141456 ca_ES
dc.identifier.issn 1932-6203
dc.identifier.uri http://hdl.handle.net/10854/4418
dc.description.abstract Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. Results MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1- specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. ca_ES
dc.format application/pdf
dc.format.extent 20 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Plos One ca_ES
dc.rights Aquest document està subjecte a aquesta llicència Creative Commons ca_ES
dc.rights.uri http://creativecommons.org/licenses/by/3.0/es/ ca_ES
dc.subject.other Sida -- Tractament ca_ES
dc.subject.other VIH (Virus) ca_ES
dc.title A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1371/journal.pone.0141456
dc.rights.accesRights info:eu-repo/semantics/openAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a WOS/JCR ca_ES
dc.indexacio Indexat a SCOPUS ca_ES

Files in this item

Show simple item record

Aquest document està subjecte a aquesta llicència Creative Commons Except where otherwise noted, this item's license is described as Aquest document està subjecte a aquesta llicència Creative Commons

Search RIUVic


Browse

Statistics